{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910143983503321"]
[null,null,"Titolo",null,"Drug discovery and development . Volume 2 Drug development [[electronic resource] /] / edited by Mukund S. Chorghade"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, N.J., : Wiley-Interscience, c2007"]
[null,null,"ISBN",null,"1-281-00213-5"]
[{"$nulls":4},"9786611002138"]
[{"$nulls":4},"0-470-08522-3"]
[{"$nulls":4},"0-470-08521-5"]
[null,null,"Descrizione fisica",null,"1 online resource (401 p.)"]
[null,null,"Disciplina",null,"615.1072"]
[{"$nulls":4},"615.19"]
[null,null,"Soggetti",null,"Drug development"]
[{"$nulls":4},"Pharmacology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; Contributors; Preface; 17 Bioactive Molecules in Medicinal Plants: A Perspective on Their Therapeutic Action; 17.1 Introduction; 17.2 Evolutionary Relationships Among Plants and Humans; 17.3 Traditional Wisdom; 17.4 Unique Libraries for Plants; 17.5 Drugs and Bioactive Molecules from Plants; 17.6 Synergism in Herbal Formulations; 17.7 Interactions Between Modern Drugs and Natural Products; 17.8 Bioavailability and Bioefficacy Enhancers; 17.9 Combination Therapies in Modern Drugs; 17.10 Role of Developments in Technologies and Analytical Tools"]
[{"$nulls":4},"17.10.1 Developments in Separation Technologies17.10.2 Developments in Combined Techniques and Advanced Technologies; 17.10.3 Molecular Farming and Bioengineering of Medicinal Plants; 17.10.4 High-Throughput Screening of Natural Products; 17.11 Herbal Medicine: The Best Possible Route to Health Care; References; 18 Natural Products as an Inspiration for the Discovery of New High-Throughput Chemical Synthesis Tools; 18.1 Introduction; 18.2 Solid-Supported Reagents as Tools in Natural Product Synthesis; 18.3 Multistep Use of Supported Reagents in Natural Product Synthesis; 18.4 Conclusions"]
[{"$nulls":4},"References19 Insulin Sensitizers: Emerging Therapeutics; 19.1 Introduction; 19.2 Therapeutic Interventions; 19.3 Discovery of Insulin "]
[{"$nulls":4},"Sensitizers; 19.4 Journey Toward New Drugs; 19.5 Conclusions; References; 20 Criteria for Industrial Readiness of Chiral Catalysis Technology for the Synthesis of Pharmaceuticals; 20.1 Introduction; 20.2 Criteria for Technology Readiness; 20.3 Examples of Industrially Ready Chiral Catalytic Technologies and Their Application; 20.3.1 Lipase Bioresolution: Ethyl 3-Amino-3-Phenylpropionate; 20.3.2 Aminoacylase Bioresolution of N-Acylamino Acids"]
[{"$nulls":4},"20.3.3 Asymmetric Hydrogenation of Prochiral Olefins by Rhodium-DuPhos Catalysts20.3.4 Asymmetric Hydrogenation of Prochiral Ketones by Ruthenium-Biphosphine-Diamine Catalysts; 20.3.5 Asymmetric Hydroformylation with Rhodium-Phosphite Catalysts; 20.3.6 Asymmetric Allylic Substitution with Palladium-Based Catalysts; 20.4 How Industrially Ready Technology Can Deliver Commercial Advantages; 20.5 Conclusions; References; 21 Enantioselective Synthesis of Propargyl Alcohols as Multifunctional Synthons; 21.1 Introduction; 21.2 Asymmetric Reduction of Prochiral α, β-Alkynyl Ketones"]
[{"$nulls":4},"21.3 Addition of Acetylenic Anion to Carbonyl Carbon21.4 Desymmetrization and Enzymatic Strategies for Chiral Propargyl Alcohol Synthesis; 21.5 β-Elimination Strategy and Miscellaneous Approaches; 21.6 Conclusions; References; 22 Carbohydrates: From Chirons to Mimics; 22.1 Introduction; 22.2 Synthetic Strategies for C-Glycosides; 22.3 Synthetic Strategies for Carbon-Linked Disaccharides and Pseudosaccharides; References; 23 Meeting the Challenges of Process Development and Scale-up of Active Pharmaceutical Ingredients; 23.1 Introduction; 23.1.1 Drug Development in the Pharmaceutical Industry"]
[{"$nulls":4},"23.1.2 Challenges in Developing and Scaling Up Chemical Processes"]
[null,null,null,"Sommario/riassunto","From first principles to real-world applications-here is the first comprehensive guide to drug discovery and development Modern drug discovery and development require the collaborative efforts of specialists in a broadarray of scientific, technical, and business disciplines-from biochemistry to molecular biology, organic chemistry to medicinal chemistry, pharmacology to marketing. Yet surprisingly, until now, there were no authoritative references offering a complete, fully integrated picture of the process. The only comprehensive guide of its kind, this groundbreaking two-volume re"]